ICR Westwicke is an IPO advisory, capital markets advisory, and strategic communications firm. We provide integrated investor relations, public relations, and independent capital markets advice to small and mid-cap healthcare companies.
We work with private and public healthcare companies to help position their story properly with all critical stakeholders and to develop value-added strategies to build brand awareness, corporate reputation and enhance equity market value. Through an integrated approach, we provide a one-stop-shop for the full spectrum of communications needs across the entire corporate lifecycle from early stage start-up to mature public company.
Our background is unique. Our investor relations partners all come directly from Wall Street as former sell-side research analysts, institutional salesmen, investment bankers, equity capital markets professionals, buy-side analysts and portfolio managers, while our public relations team are former agency veterans, corporate communications executives and journalists.
Learn more
Latest Blog Posts
-
February 27th, 2024
Is 2024 the Year for the Life Science IPO Market?
Since November 2023, the IPO market for companies has shown some signs of life – dare we say, “green shoots.” Over the most recent 15-week period, 10 firms transition to their new chapters as publicly listed companies. In 8 of the 10 cases, the stock price has risen above the new issue price, with notable […]
-
January 22nd, 2024
Medical Technology in 2024 – Thoughts and Predictions for the Year Ahead
With the J.P. Morgan Healthcare Conference behind us, now is the ideal time to opine on what the future holds for the MedTech sub-sector in 2024. See below for several thoughts and key takeaways on the general sentiment and outlook for MedTech this year. This is my personal view, which has been informed in part […]
-
January 15th, 2024
AI in Healthcare: Gaining Momentum in 2024
Artificial Intelligence (AI), instrumental in many healthcare trends of 2023, promises to dramatically gain momentum in 2024. Continue on for an outlook for 2024.